Landiolol hydrochloride for prevention of postoperative atrial fibrillation after esophageal cancer surgery: The double-blind, randomized, placebo-controlled trial

Landiolol hydrochloride for prevention of postoperative atrial fibrillation after esophageal cancer surgery: The double-blind, randomized, placebo-controlled trial - APPLE trial Phase III (A Prophylactic study using Placebo or Landiolol after Esophagectomy)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010648

Enrollment

100

Registered

2013-05-04

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Intravenous placebo Glucose 5% after operation. Intravenous landiolol hydrochloride after operation, 3 gamma, 72 hr.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients undergoing a right transthoracic esophagectomy for esophageal cancer resection 2)No severe disturbance of liver function and renal function 3)Writen informed consent

Exclusion criteria

Exclusion criteria: 1)Past of arrhythmia 2)Second -or third-degree AV block 3)Sinus bradycardia at rest < 50/min 4)With pacemaker 5)Clinical heart failure 6)Doctor's decision not to register to this regimen

Design outcomes

Secondary

Measure	Time frame
Incidence of postoperative complications Blood pressure, heart rate Inflammatory index: WBC, CRP, IL-6, HMGB-1	—

Primary

Measure	Time frame
Incidence of postoperative atrial fibrillation	—

Countries

Japan

Contacts

Public ContactToshiyasu Ojima

Wakayama Medical University Second Department of Surgery

tojima@wakayama-med.ac.jp073-441-0613

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026